A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism
PHASE2CompletedINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
January 31, 2006
Primary Completion Date
September 30, 2006
Study Completion Date
November 30, 2006
Conditions
Metabolic Syndrome X
Interventions
DRUG
LY518674
Trial Locations (1)
19104
John Millar, Philadelphia
All Listed Sponsors
collaborator
Eli Lilly and Company
INDUSTRY
lead
University of Pennsylvania
OTHER
NCT00327002 - A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism | Biotech Hunter | Biotech Hunter